OptiBiotix Health PLC Consumer study of LPLDL in Cholbiome products
01 Febbraio 2022 - 07:59AM
RNS Non-Regulatory
TIDMOPTI
OptiBiotix Health PLC
01 February 2022
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Consumer study of LP(LDL) (R) in Cholbiome(R) products
OptiBiotix Health p lc (AI M: OPTI), a life sciences busi ness d
eveloping compou n ds to tackle obesity, high cholesterol, blood
pressure, diabetes, announces that its wholly-owned subsidiary,
ProBiotix Health Ltd. ("ProBiotix"), has carried out a consumer
study (n=46) on its CholBiome(R) products.
CholBiome(R)X3 and CholBiome(R)BP are ProBiotix's patented and
proprietary formulations developed to reduce cardiovascular disease
risk using the probiotic strain LP(LDL) (R), on which a third
double-blind, randomised, placebo-controlled human clinical study
was recently published documenting a statistical significant effect
of LP(LDL) (R) in reducing total cholesterol, LDL-cholesterol and
APO-B : Third human clinical trial LPLDL(R) in hypercholesterolemic
adults - ScienceDirect . (RNS: 18 January 2022)
Human studies are essential in providing a scientific, clinical,
and statistical evidence base for use of an intervention in a
controlled environment. However, it's important to check these
findings reflect the real-world use of products which is best
assessed by receiving structured feedback from consumers of a
product.
The consumer study was carried out by contacting customers who
purchased CholBiome(R) products from the website
https://optibiotix.online .
The results of the survey are shown below:-
I. 96% of consumers who had taken CholBiome(R)X3 and who had
measured their total cholesterol levels reported that their levels
had reduced. Of these:-
a. 17% reported reductions in total cholesterol of >30%
b. 50% reported reductions in total cholesterol of between 16-30%
c. 29% reported reductions in total cholesterol of between 1-15%
II. 88% of consumers stated that their LDL-cholesterol (bad
cholesterol) had been reduced (with 8% not knowing their LDL
cholesterol levels).
III. This level of reduction was sustained with 93% of users who
took the product for more than 1 year reporting reduced levels of
total and LDL cholesterol.
IV. No consumers taking CholBiome(R)X3 reported any side effects
or tolerance issues.
These results build upon a consumer study carried out in Dec
2019 (n=20) on CholBiome(R)X3 in which 95% of users stating that
the product was effective, and 90% reporting they would recommend
the product to family and friends.
Mikkel Hvid-Hansen, Commercial Director of Probiotics,
commented: "The combination of scientific, clinical, and consumer
studies on LP(LDL) (R), and formulations like the CholBiome(R)
product range provide a growing body of evidence for its safe and
effective use in reducing biomarkers of cardiovascular risk like
total cholesterol, LDL cholesterol, and Apolipoprotein B. We now
have five scientific publications, three human studies, two
consumer studies and numerous positive product reviews which gives
us confidence in the use of LP(LDL) (R). We now feel we have
evidence broadly comparable to Phase I/II pharmaceutical studies
which we can use to open up further partnering or licensing
opportunities for use of LP(LDL) (R) as an OTC product by itself or
in combination with existing treatments (e.g. statins), or as a
drug biotherapeutic in markets outside the USA."
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cenkos Securities plc (Broker) Tel: 020 7397 8900
Callum Davidson / Neil McDonald
Michael Johnson / Russell Kerr (Sales)
Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy
This communication is a "Reach" announcement. Reach is a
non-regulatory news service. By using this service an issuer is
confirming that the information contained in this announcement is
of a non-regulatory nature. Information required to be notified
under the AIM Rules for Companies, Market Abuse Regulation or other
regulation would be disseminated as an RNS regulatory announcement
and not on RNS Reach.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRABKDBPABKDCDN
(END) Dow Jones Newswires
February 01, 2022 01:59 ET (06:59 GMT)
Grafico Azioni Optibiotix Health (LSE:OPTI)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Optibiotix Health (LSE:OPTI)
Storico
Da Mar 2023 a Mar 2024